Buy Or Sell Opportunity • Jul 29
Now 24% undervalued after recent price drop Over the last 90 days, the stock has fallen 30% to ₩21,800. The fair value is estimated to be ₩28,517, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 22%. Reported Earnings • Mar 18
Full year 2025 earnings released: EPS: ₩2,534 (vs ₩2,644 in FY 2024) Full year 2025 results: EPS: ₩2,534 (down from ₩2,644 in FY 2024). Revenue: ₩775.3b (up 7.8% from FY 2024). Net income: ₩61.5b (down 5.4% from FY 2024). Profit margin: 7.9% (down from 9.0% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 19% per year. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩30,050, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 53% over the past three years. Buy Or Sell Opportunity • Feb 24
Now 20% undervalued Over the last 90 days, the stock has risen 42% to ₩37,100. The fair value is estimated to be ₩46,555, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.0% over the last 3 years. Earnings per share has grown by 28%. Ankündigung • Feb 06
JW Pharmaceutical Corporation announces Annual dividend JW Pharmaceutical Corporation announced Annual dividend of KRW 500.0000 per share, ex-date on March 31, 2026 and record date on April 01, 2026. Ankündigung • Feb 06
JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2026 JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 38, gwacheon-daero 7-gil, gyeonggi-do, gwacheon South Korea Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩31,750, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 64% over the past three years. Buy Or Sell Opportunity • Nov 06
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to ₩25,300. The fair value is estimated to be ₩20,799, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 3.8% over the last 3 years. Earnings per share has grown by 37%. Reported Earnings • Mar 22
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: ₩2,644 (up from ₩1,474 in FY 2023). Revenue: ₩719.4b (down 3.9% from FY 2023). Net income: ₩65.0b (up 76% from FY 2023). Profit margin: 9.0% (up from 4.9% in FY 2023). The increase in margin was driven by lower expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.3%. Revenue is forecast to grow 7.6% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Price Target Changed • Mar 07
Price target decreased by 18% to ₩34,000 Down from ₩41,500, the current price target is provided by 1 analyst. New target price is 54% above last closing price of ₩22,050. Stock is down 34% over the past year. The company is forecast to post earnings per share of ₩2,817 for next year compared to ₩1,564 last year. Ankündigung • Feb 12
JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2025 JW Pharmaceutical Corporation, Annual General Meeting, Mar 26, 2025, at 09:01 Tokyo Standard Time. Location: jw hall, 38, gwacheon-daero 7-gil, gyeonggi-do, gwacheon South Korea Major Estimate Revision • Jan 25
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩802.7m to ₩715.9m. EPS estimate fell from ₩3,331 to ₩2,817 per share. Net income forecast to grow 15% next year vs 6.1% growth forecast for Pharmaceuticals industry in South Korea. Consensus price target down from ₩41,500 to ₩39,500. Share price rose 3.9% to ₩24,150 over the past week. Ankündigung • Jan 21
JW Pharmaceutical Corporation Obtains Marketing Authorization from the Ministry of Food and Drug Safety for the Oral Spleen Tyrosine Kinase Inhibitor Tavalisse JW Pharmaceutical Corporation has obtained marketing authorization from the Ministry of Food and Drug Safety (MFDS) for the oral spleen tyrosine kinase (SYK) inhibitor Tavalisse (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic idiopathic thrombocytopenic purpura (ITP) who have had an insufficient response to a previous treatment. Tavalisse is an oral SYK inhibitor discovered by Rigel Pharmaceuticals Inc. It suppresses platelet destruction by macrophages and platelet depletion, thereby improving the bleeding symptoms caused by ITP. As a result of obtaining marketing authorization, it is expected that a new treatment option will be provided to chronic ITP patients in Korea. Upcoming Dividend • Dec 20
Upcoming dividend of ₩392 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 1.7%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.1%). Declared Dividend • Nov 13
Dividend of ₩392 announced Shareholders will receive a dividend of ₩392. Ex-date: 27th December 2024 Payment date: 28th April 2025 Dividend yield will be 1.6%, which is higher than the industry average of 1.1%. Sustainability & Growth Dividend is well covered by both earnings (26% earnings payout ratio) and cash flows (11% cash payout ratio). The dividend has increased by an average of 8.2% per year over the past 8 years and payments have been stable during that time. EPS is expected to grow by 116% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • Sep 03
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (4.7% net profit margin). Shareholders have been diluted in the past year (5.4% increase in shares outstanding). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₩25,500, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 16x in the Pharmaceuticals industry in South Korea. Negligible returns to shareholders over past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩10,226 per share. Reported Earnings • May 19
First quarter 2024 earnings released: EPS: ₩816 (vs ₩643 in 1Q 2023) First quarter 2024 results: EPS: ₩816 (up from ₩643 in 1Q 2023). Revenue: ₩180.6b (up 4.2% from 1Q 2023). Net income: ₩20.1b (up 29% from 1Q 2023). Profit margin: 11% (up from 9.0% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.2% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Mar 26
Now 21% overvalued Over the last 90 days, the stock has fallen 6.6% to ₩34,650. The fair value is estimated to be ₩28,755, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 96% in the next 2 years. Reported Earnings • Mar 19
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: EPS: ₩1,504 (up from ₩1,305 in FY 2022). Revenue: ₩748.5b (up 9.4% from FY 2022). Net income: ₩37.0b (up 16% from FY 2022). Profit margin: 4.9% (up from 4.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 17%. Revenue is forecast to grow 8.6% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 107% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Mar 07
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 10.0% to ₩33,000. The fair value is estimated to be ₩27,246, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 19% in 2 years. Earnings are forecast to grow by 196% in the next 2 years. Price Target Changed • Jan 18
Price target increased by 22% to ₩40,163 Up from ₩33,000, the current price target is an average from 3 analysts. New target price is 9.1% above last closing price of ₩36,800. Stock is up 98% over the past year. The company is forecast to post earnings per share of ₩2,417 for next year compared to ₩1,361 last year. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩37,250, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 24% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩56,869 per share. New Risk • Nov 21
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₩30,200, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 4.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩56,869 per share. New Risk • Oct 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks High level of debt (51% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (6.2% increase in shares outstanding). Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩30,700, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 9.8% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩57,787 per share. Buying Opportunity • Aug 18
Now 21% undervalued Over the last 90 days, the stock is up 85%. The fair value is estimated to be ₩57,787, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 19% in 2 years. Earnings is forecast to grow by 80% in the next 2 years. Valuation Update With 7 Day Price Move • Aug 09
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩42,300, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩57,787 per share. Price Target Changed • Jul 15
Price target increased by 7.7% to ₩36,245 Up from ₩33,660, the current price target is an average from 4 analysts. New target price is 6.9% above last closing price of ₩33,900. Stock is up 41% over the past year. The company is forecast to post earnings per share of ₩2,546 for next year compared to ₩1,388 last year. New Risk • Jul 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.2% average weekly change). Valuation Update With 7 Day Price Move • Jul 13
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₩30,450, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 13x in the Pharmaceuticals industry in South Korea. Total returns to shareholders of 2.9% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩38,264 per share. Reported Earnings • Mar 18
Full year 2022 earnings released: EPS: ₩1,331 (vs ₩41.00 loss in FY 2021) Full year 2022 results: EPS: ₩1,331 (up from ₩41.00 loss in FY 2021). Revenue: ₩684.4b (up 13% from FY 2021). Net income: ₩31.9b (up ₩32.9b from FY 2021). Profit margin: 4.7% (up from net loss in FY 2021). Revenue is forecast to grow 6.6% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Dec 21
Upcoming dividend of ₩375 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 02 May 2023. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of South Korean dividend payers (3.3%). Higher than average of industry peers (1.0%). Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Price Target Changed • Oct 04
Price target decreased to ₩33,000 Down from ₩36,333, the current price target is an average from 3 analysts. New target price is 80% above last closing price of ₩18,350. Stock is down 20% over the past year. The company is forecast to post earnings per share of ₩1,868 next year compared to a net loss per share of ₩43.68 last year. Price Target Changed • Apr 27
Price target increased to ₩40,000 Up from ₩9,797, the current price target is provided by 1 analyst. New target price is 40% above last closing price of ₩28,650. Stock is up 1.1% over the past year. The company posted a net loss per share of ₩43.81 last year. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. No independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Upcoming Dividend • Dec 22
Upcoming dividend of ₩316 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 25 April 2022. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (2.4%). Higher than average of industry peers (0.8%). Reported Earnings • Mar 21
Full year 2020 earnings released: ₩676 loss per share (vs ₩1,158 loss in FY 2019) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: ₩547.3b (up 7.0% from FY 2019). Net loss: ₩15.2b (loss narrowed 40% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 98% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 08
New 90-day low: ₩30,550 The company is down 2.0% from its price of ₩31,262 on 10 November 2020. The South Korean market is up 25% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period. Is New 90 Day High Low • Jan 04
New 90-day high: ₩36,200 The company is up 9.0% from its price of ₩33,252 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 19% over the same period. Is New 90 Day High Low • Dec 21
New 90-day high: ₩36,500 The company is up 1.0% from its price of ₩36,150 on 22 September 2020. The South Korean market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Reported Earnings • Nov 20
Third quarter 2020 earnings released: EPS ₩134 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ₩137.1b (up 3.1% from 3Q 2019). Net income: ₩2.95b (up 158% from 3Q 2019). Profit margin: 2.2% (up from 0.9% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 107% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Oct 16
New 90-day low: ₩31,950 The company is down 6.0% from its price of ₩34,000 on 17 July 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Is New 90 Day High Low • Sep 18
New 90-day high: ₩40,800 The company is up 5.0% from its price of ₩38,800 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 26% over the same period. 
